IR@PKUHSC  > 北京大学第三临床医学院
学科主题临床医学
Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment
Zhou, Dao-bin1; Yu, Li2; Du, Xin3; Jin, Jie4; Cai, Zhen4; Chen, Fangping5; Ke, Xiaoyan6; Li, Xiao7; Wu, Depei8; Meng, Fanyi9; Ai, Huisheng10; Zhang, Jingshan11; DeMarco, Dena11; Chen, Nianhang11; Mei, Jay11; Wang, Jianmin12; Hou, Jian13
关键词Chinese Multiple Myeloma Relapsed/refractory Renal Insufficiency Lenalidomide
刊名INTERNATIONAL JOURNAL OF HEMATOLOGY
2015-06-01
DOI10.1007/s12185-015-1771-7
101期:6页:569-577
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Hematology
研究领域[WOS]Hematology
关键词[WOS]FAILURE ; PHARMACOKINETICS ; REVERSIBILITY ; PATHOGENESIS ; AGENTS ; IMPACT
英文摘要

Lower starting doses of lenalidomide (LEN) are recommended for patients with renal impairment (RI). In the present study, we conducted a subgroup analysis of the MM-021 registration trial to investigate the efficacy and safety of LEN plus low-dose dexamethasone (LoDEX) in Chinese patients with advanced relapsed or refractory multiple myeloma (RRMM) based on levels of RI. Patients received LEN+LoDEX until disease progression or discontinuation. Patients were divided according to RI: no/mild [creatinine clearance (CrCl) >= 60 mL/min, n = 131], moderate (CrCl >= 30 to <60 mL/min, n = 54), and severe (CrCl <30 mL/min, n = 14). LEN starting dose was 25 mg/day on days 1-21, adjusted for baseline renal function. Best overall response rate was 48 %; in patients with no/mild, moderate, or severe RI, response rates were 50, 42, and 42 %, respectively. Median progression-free survival and overall survival were longer in patients with no/mild RI (9.3 and 22.4 months, respectively) versus those with moderate (6.9 and 16.0 months) or severe RI(4.8 and 11.1 months). LEN+LoDEX was well tolerated, although incidences of grade 3-4 neutropenia, anemia, and thrombocytopenia were higher in patients with severe RI. In Chinese patients with advanced RRMM and RI, adjusting the starting dose of LEN according to renal function did not compromise the efficacy or safety of LEN+LoDEX.

语种英语
WOS记录号WOS:000357519200007
资助机构Celgene Corporation
引用统计
被引频次:4[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/55468
专题北京大学第三临床医学院
作者单位1.Beijing Union Med Coll Hosp, Dept Hematol, Beijing 100730, Peoples R China
2.Chinese Peoples Liberat Army Gen Hosp, Hosp 301, Beijing 100853, Peoples R China
3.Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
4.Zhejiang Univ, Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China
5.Cent S Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China
6.Peking Univ, Hosp 3, Beijing 100871, Peoples R China
7.Shanghai 6th Hosp, Shanghai, Peoples R China
8.Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
9.Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China
10.307 PLA Hosp, Beijing, Peoples R China
11.Celgene Corp, Summit, NJ USA
12.Changhai Hosp, Shanghai, Peoples R China
13.Shanghai Changzheng Hosp, Shanghai, Peoples R China
推荐引用方式
GB/T 7714
Zhou, Dao-bin,Yu, Li,Du, Xin,et al. Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment[J]. INTERNATIONAL JOURNAL OF HEMATOLOGY,2015,101(6):569-577.
APA Zhou, Dao-bin.,Yu, Li.,Du, Xin.,Jin, Jie.,Cai, Zhen.,...&Hou, Jian.(2015).Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment.INTERNATIONAL JOURNAL OF HEMATOLOGY,101(6),569-577.
MLA Zhou, Dao-bin,et al."Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment".INTERNATIONAL JOURNAL OF HEMATOLOGY 101.6(2015):569-577.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhou, Dao-bin]的文章
[Yu, Li]的文章
[Du, Xin]的文章
百度学术
百度学术中相似的文章
[Zhou, Dao-bin]的文章
[Yu, Li]的文章
[Du, Xin]的文章
必应学术
必应学术中相似的文章
[Zhou, Dao-bin]的文章
[Yu, Li]的文章
[Du, Xin]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。